FGFR2, fibroblast growth factor receptor 2, 2263

N. diseases: 731; N. variants: 141
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE Loss of the intrinsic FGF7/FGF10-type 2 FGF receptor (FGFR2) pathway and gain of the ectopic type 1 FGF receptor (FGFR1) pathway are associated with the progression to malignancy in prostate cancer (PCa) and many other epithelial originating lesions. 30761180 2019
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE The serum expression levels of miR-628, prostate-specific antigen, fibroblast growth factor 1, and FGFR2 were examined in patients with PCa. 31316598 2019
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE Thus, we tested the possibility that FGFR2 negatively regulates the hypoxia-triggered metastasis of prostate cancer. 30837551 2019
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE Importantly, the KLK2-FGFR2 fusion represents a novel target for precision therapies and should be screened for in men with prostate cancer. 31043681 2019
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation disease BEFREE Application of this assay on prospective patient samples uncovered OLFM4 as a novel RET fusion partner in a small-bowel cancer and led to the discovery of a KLK2-FGFR2 fusion in a patient with prostate cancer who subsequently underwent treatment with a pan-fibroblast growth factor receptor inhibitor. 28802831 2017
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation disease GWASCAT Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 27197191 2016
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE Abnormalities of FGFR2 have been shown in advanced prostate cancer or prostate cancer cell lines, and we previously demonstrated the tumor-suppressive effects of the restoration of FGFR2IIIb in prostate cancer cells. 24839986 2014
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation disease BEFREE Through a prospective clinical sequencing program for advanced cancers, four index cases were identified which harbor gene rearrangements of FGFR2, including patients with cholangiocarcinoma, breast cancer, and prostate cancer. 23558953 2013
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE FGFR2, WWOX, E-Cadherin, PKCmu, and RASLL1A did not display noteworthy methylation in pCA (0-1%) or in BPH. 16956712 2007
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE These findings propose that decreased expression of not only FGFR2(IIIb) but also FGFR2(IIIc) isoforms may be a critical step in prostate cancer progression and furthermore suggest that FGFR2(IIIb) expression could be used as a marker for prostate cancer evolution from androgen-dependent to androgen-independent status. 12111699 2002
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 AlteredExpression disease BEFREE In most cases of prostate cancer there are no changes in alternative splicing of FGF receptors, but in a subgroup there is increased expression of the FGFR-2 IIIc isoform. 11170144 2001
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation disease BEFREE FGFR2 mutations in the-FGF binding domain and the TMD are not frequent events in human prostate cancer. 11069376 2000
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 AlteredExpression disease BEFREE In addition, we have observed overexpression of both FGFR-1 and FGFR-2 in the prostate cancer epithelial cells in a subset of prostate cancers and that such overexpression is correlated with poor differentiation. 10353739 1999
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker disease BEFREE These findings lend support to the hypothesis that that loss of FGF-R2(IIIb) may be one step in a series of events which lead to progression of human prostate cancer. 9444954 1997